Prospective, Single center, Registry to Evaluate the Long-term Clinical Safety and Efficacy of the Resolute Integrity drug eluting stent in an all-comers population. - Resolute Integrity-KUKI Registry

Department of Cardiovascular Internal Medicine, Kuki General Hospital0 个研究点目标入组 1,000 人开始时间: 2013年1月31日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1.Patients with cardiogenic shock 2.Patients who are pregnant or possibly pregnant 3.Patients who cannot comply with the antiplatelet therapy specified for this clinical study 4.Patients scheduled to undergo elective surgery within 6 months post-index PCI 5.Patients with a history of allergic reaction or hypersensitivity to zotarolimus, sirolimus, tacrolimus, everolimus, or other analogues or derivatives 6.Patients with an allergic reaction to antiplatelet or anticoagulant drugs, such as heparin, aspirin, ticlopidine, or clopidogrel, or contrast agents, or those who cannot tolerate these substances and to whom appropriate treatments cannot be given 7. Patient who underwent stent treatment with BMS in other lesions within 6 months prior to the conduct of index PCI of the target vessel

发起方

Department of Cardiovascular Internal Medicine, Kuki General Hospital